The report also provides a detailed analysis of the current Diabetic Foot Ulcers marketed drugs and late-stage pipeline drugs. The rising cases of chronic diabetes due to poor glycemic control coupled with the increasing unmet need for effective drugs to address this illness are primarily driving the market.